Compare YieldMax COIN Option Income Strategy ETF (CONY) vs Quest Diagnostics Inc (DGX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
YieldMax COIN Option Income Strategy ETF vs Quest Diagnostics Inc — how do they compare? YieldMax COIN Option Income Strategy ETF trades at $18.1, while Quest Diagnostics Inc trades at $237.46 (market cap $26.21B). The key difference: Quest Diagnostics Inc pays a 1.45% dividend while YieldMax COIN Option Income Strategy ETF pays none, and Quest Diagnostics Inc is trading nearer its 52-week high, YieldMax COIN Option Income Strategy ETF nearer its low. Which is the better fit depends on your goals.
| CONY | DGX | |
|---|---|---|
Sector | Income / Options Overlay | Health |
52-Week High | $76.50 | $238.50 |
52-Week Low | $17.80 | $173.49 |
Market Cap | — | $26.21B |
Enterprise Value | — | $31.97B |
Dividend Yield | — | 1.45% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CONY trades at $18.05, down 0.11% with a bearish technical signal from moving averages. The ETF shows weekly dividend distributions but lacks fundamental valuation metrics. Recent news highlights investor losses despite high yield promises, with articles questioning the fund's long-term sustainability as a Coinbase proxy.
Outlook remains cautious due to structural concerns about the option income strategy capping upside potential. Investment opportunity centers on high distribution yields, but risks include underlying asset volatility and negative media sentiment questioning the fund's value proposition for long-term holders.
Quest Diagnostics (DGX) trades at $237.63, down slightly by 0.3% today, but maintains strong momentum with three consecutive quarterly earnings beats and a raised 2026 outlook. The stock shows bullish technical signals with moving averages supporting upward trends, while fundamentals reveal solid revenue growth to $11.04 billion in 2025 and improving profit margins. Recent news highlights surging testing demand and AI implementation driving operational efficiency.
DGX presents a favorable investment case with analyst consensus price target of $249.50 offering 5% upside potential. Strong testing demand, strategic partnerships, and earnings momentum support growth, though elevated debt levels and margin pressures from lower-margin deals pose moderate risks. The stock's current valuation at 25.21 P/E appears reasonable given growth prospects.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About YieldMax COIN Option Income Strategy ETF
CONY is an actively managed ETF that seeks to generate weekly income by selling call options on Coinbase (COIN) stock. It aims to provide high yield while maintaining exposure to the price movements of the crypto exchange.
Read more on CONY →About Quest Diagnostics Inc
Quest Diagnostics is a leading independent provider of diagnostic testing, information, and services in the U.S. The company generates over 95% of its revenue through clinical testing, anatomic pathology, esoteric testing, and substance abuse testing with specimens collected at its national network of roughly 2,300 patient service centers, as well as multiple doctors offices and hospitals. The firm also runs a much smaller diagnostic solutions segment that provides clinical trials testing, risk assessment services, and information technology solutions.
Read more on DGX →
